Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Improvemf: Phase 1b trial of imetelstat plus ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

TBTerrence BradleyHYHabte YimerYYYiqun Yang

Discussion

Loading...

Member takes

Overview

Phase 1b trial shows improved symptom response in patients with myelofibrosis treated with imetelstat and ruxolitinib, suggesting enhanced treatment potential.

Key Points

  • Imetelstat plus ruxolitinib treatment improved symptoms of myelofibrosis in patients.
  • The trial plans to enroll approximately 30 patients to evaluate safety and efficacy.
  • Phase 1b part focuses on symptomatic patients with myelofibrosis and intends to deliver changes in symptom score.
  • This could support future combination therapies for patients unresponsive to JAK inhibitors.

Cite This Study

Bradley et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d794https://doi.org/10.1182/blood-2025-2052
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A phase I study of the combination of ruxolitinib and the ERK1/2 inhibitor ulixertinib in previously treated myelofibrosis patients.2025
  2. 2A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant–selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia2025 · 2 citations
  3. 3A phase II study evaluating the efficacy and safety of imetelstat in patients with advanced myelodysplastic neoplasms or AML failing HMA-based therapy – interim analysis results of the IMpress study2025 · 1 citations
  4. 4Preliminary analysis of a phase 2b, randomized, active-control study of flonoltinib maleate (FM) vs. ruxolitinib in intermediate-2 or high-risk myelofibrosis patients2025 · 1 citations
  5. 5Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics2025